Hospital
Suburban Hospital, INC.
Suburban Hospital, INC. was paid $3.28M by Medicaid between Jan 2018 and Dec 2024, across 75 billing codes. Its largest line is 99284, emergency room visit (serious) — 39% of everything it billed.
33Billing provider infoSUBURBAN HOSPITAL, INC.
BETHESDA, MD 20814
BETHESDA, MD 20814
33aNPI1205896446assigned 03/23/2006
33bProvider typePsychiatric Hospital
28Total paid$3.28M
24GClaims104,616
24DCodes billed75
24AFirst – last monthJan 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 20,323 | $746K | |
| 2019 | 18,544 | $482K | |
| 2020 | 9,827 | $401K | |
| 2021 | 14,678 | $506K | |
| 2022 | 17,403 | $555K | |
| 2023 | 14,402 | $333K | |
| 2024incomplete | 9,439 | $253K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 39% | 5,245 | 4,660 | $1.26M |
| G0378 | Hospital observation service, per hour | 21% | 1,156 | 942 | $698K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 19% | 4,308 | 3,719 | $624K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 4.0% | 2,182 | 1,732 | $131K |
| 80053 | Comprehensive metabolic panel | 3.2% | 9,295 | 7,086 | $104K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.4% | 846 | 706 | $79K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.3% | 187 | 172 | $75K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.4% | 9,454 | 7,720 | $47K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,969 | 1,699 | $29K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,532 | 1,398 | $24K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 475 | 424 | $23K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,696 | 2,399 | $21K |
63 more codes
| 84484 | <1% | 4,684 | $21K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,027 | $13K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 457 | $12K |
| J3490 | Unclassified drugs | <1% | 1,211 | $10K |
| 81001 | <1% | 3,391 | $9K | |
| 87040 | <1% | 564 | $8K | |
| 85610 | <1% | 4,541 | $7K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 216 | $7K |
| 83690 | <1% | 2,898 | $5K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 681 | $5K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,364 | $5K |
| 83735 | <1% | 3,743 | $5K | |
| 87631 | <1% | 169 | $4K | |
| A9270 | Non-covered item or service | <1% | 13,870 | $4K |
| 85730 | <1% | 2,577 | $4K | |
| 82962 | <1% | 2,565 | $4K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 408 | $4K |
| J2704 | Injection, propofol, 10 mg | <1% | 1,399 | $3K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 431 | $3K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,898 | $2K |
| 84703 | <1% | 188 | $2K | |
| 85027 | <1% | 1,295 | $2K | |
| 82077 | <1% | 140 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 642 | $2K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,210 | $2K |
| 86850 | <1% | 83 | $2K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,428 | $1K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 705 | $1K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 490 | $1K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 164 | $1K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,252 | $922.16 |
| 83605 | <1% | 791 | $919.85 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 676 | $801.73 |
| 71046 | Radiologic examination, chest; 2 views | <1% | 62 | $784.58 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 340 | $733.90 |
| 83880 | <1% | 209 | $604.65 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 63 | $554.75 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 762 | $517.76 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 64 | $457.02 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 142 | $381.48 |
| 90715 | <1% | 26 | $303.88 | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 31 | $303.32 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 56 | $249.66 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 84 | $156.02 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 50 | $143.10 |
| C1769 | Guide wire | <1% | 31 | $130.62 |
| 82150 | <1% | 28 | $74.88 | |
| 86901 | <1% | 42 | $61.45 | |
| 86900 | <1% | 42 | $61.45 | |
| J1815 | Injection, insulin, per 5 units | <1% | 19 | $42.79 |
| 80061 | Lipid panel | <1% | 13 | $35.03 |
| 84132 | <1% | 384 | $22.31 | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 0% | 127 | $0.00 |
| 82435 | 0% | 206 | $0.00 | |
| 97162 | 0% | 29 | $0.00 | |
| 84443 | Thyroid stimulating hormone (TSH) | 0% | 12 | $0.00 |
| 84295 | 0% | 229 | $0.00 | |
| 82947 | 0% | 198 | $0.00 | |
| 85014 | 0% | 217 | $0.00 | |
| 84520 | 0% | 205 | $0.00 | |
| 82565 | 0% | 223 | $0.00 | |
| G1012 | Clinical decision support mechanism agilemd, as defined by the medicare appropriate use criteria program | 0% | 185 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 34 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSIDONE, LEIGHANN (PRESIDENT)